Objective    To investigate the clinical and laboratorial features of acute mixed lineage leukemia (AMLL)

as well as its chemotherapeutic and effect prognosis.     Methods    AMLL was diagnosed according to the findings of morphology

cytochemistry and the immunophenotype of bone marrow cells. Therapeutic outcome was evaluated and the relative factors were analyzed.      Results    Clinical presentations of 8 AMLL patients included fever

enlargement of the lymph nodes

spleen and/or liver. Half patients belonged to hyper-leukocytic leukemia. The marrows of all the patients were markedly hypercellular with leukemic cells accounting for 0.86(0.79-0.96). The immunophenotypes of 8 patients wer

e all B-Ly/My

+

 phenotype. Seven of the 8 patients received the induction chemotherapy with the regimen targeting both myeloid and lymphoid lineage

in whom 6 patients were completely remitted

and 1 patient died of induction chemotherapy-related death. Three of the 6 patients were continually given chemotherapy and the duration of disease-free survival has reached to 7 months (ranging from 5 to 9 months).     Conclusion    AMLL

a specific leukemia

should be diagnozed on the overall analysis of cell morphology

cytochemistry and immunophenotype. Modality of chemotherapy for AMLL should aim at both acute lymphoid leukemia and acute nonlymphocytic leukemia. Further study is needed to elucidate the long-term prognosis of AMLL.